1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine | 885672-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine
• 英文别名: 1-(4-chlorophenyl)-3-dimethylaminopropan-1-amine；1-(4-chlorophenyl)-N3,N3-dimethylpropane-1,3-diamine；1-(4-chlorophenyl)-3-dimethylamino-propan-1-amine；1-(4-chlorophenyl)-N',N'-dimethylpropane-1,3-diamine
• CAS: 885672-69-5
• 化学式: C₁₁H₁₇ClN₂
• 分子量: 212.722
• InChiKey: BHCWWKIOLOCHRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine 、 4-苯基苯甲酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 、 四氢呋喃 为溶剂， 反应 19.0h， 以60%的产率得到1-[1-(4-chlorophenyl)-3-dimethylaminopropyl]-3-(4-phenylphenyl)-carbamide
  参考文献：
  名称：

  WO2006/135694

  摘要：

  公开号：
• 作为产物：
  描述：

  [1-(4-氯苯基)-3-羟基丙基]氨基甲酸1,1-二甲基乙酯 在 盐酸 、 四丁基碘化铵 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 6.5h， 生成 1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine
  参考文献：
  名称：

  Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

  摘要：

  Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

  DOI：

  10.1021/jm301762v

文献信息

• Novel and potent small-molecule urotensin II receptor agonists
  作者：Fredrik Lehmann、Erika A. Currier、Bryan Clemons、Lars K. Hansen、Roger Olsson、Uli Hacksell、Kristina Luthman

  DOI：10.1016/j.bmc.2009.04.062

  日期：2009.7

  A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided

  已经合成了一系列非肽尿紧张素II受体激动剂N- [1-（4-氯苯基）-3-（二甲基氨基）丙基] -4-苯基苯甲酰胺（FL104）的类似物，并进行了药理学评价。两种最有效的外消旋类似物的对映异构体获自相应的非对映体扁桃酰胺。与先前观察到的SAR一致，大多数激动剂效力存在于（S）对映异构体中。新系列中最有效的UII受体激动剂是（S）-N- [3-二甲基氨基-1-（2-萘基丙基）丙基] -4-（4-氯苯基）苯甲酰胺（ 在尿紧张素II处EC 50 = 23 nM受体）。
• [EN] PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS<br/>[FR] DÉRIVÉS PYRROLO[2,3-D]PYRIMIDINE COMME INHIBITEURS DE LA PROTÉINE KINASE B
  申请人：ASTRAZENECA AB

  公开号：WO2009047563A1

  公开（公告）日：2009-04-16

  The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

  该发明涉及一类新型化合物，其化学式为（I）或其盐：其中Y、Z1、Z2、R1、R4、R5和n如规范中所述，这些化合物可能在通过蛋白激酶B（PKB）介导的疾病或医疗状况的治疗或预防中有用，例如癌症。该发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗通过PKB介导的疾病的方法，以及制备化合物（I）的方法。
• UII-modulating compounds and their use
  申请人：Luthman Kristina Ingrid

  公开号：US20070043104A1

  公开（公告）日：2007-02-22

  Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.

  本文披露了新型芳香族含有化合物及其在治疗和预防与Urotensin II受体相关的疾病和疾病障碍方面的应用方法。
• Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
  申请人：AstraZeneca AB

  公开号：US08101623B2

  公开（公告）日：2012-01-24

  The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I), methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

  本发明涉及一类新的化合物组合式（I）或其盐：其中Y、Z1、Z2、R1、R4、R5和n的描述如规范中所述，这些化合物可以用于治疗或预防通过蛋白激酶B（PKB）介导的疾病或医疗情况，如癌症。本发明还涉及包含化合物组合式（I）的制药组合物、使用该化合物治疗PKB介导的疾病的方法以及制备化合物组合式（I）的方法。
• Novel Protein Kinase B Inhibitors - 060
  申请人：Johnson Paul David

  公开号：US20120190679A1

  公开（公告）日：2012-07-26

  The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z 1 , Z 2 , R 1 , R 4 , R 5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

  本发明涉及一种新型化合物组，其化学式为（I）或其盐： 其中Y、Z1、Z2、R1、R4、R5和n如规范中所述，可以用于治疗或预防通过蛋白激酶B（PKB）介导的疾病或医疗情况，如癌症。本发明还涉及包含所述化合物的制药组合物，使用所述化合物治疗由PKB介导的疾病的方法以及制备化合物（I）的方法。